The antimicrobial agent, 6-(p-hydroxyphenylazo)-uracil, specifically inhibits DNA polymerase III of Bacillus subtilis with a Ki of less than 1 pM. The inhibition requires prior reduction of the drug, is reversible, and is competitive with dGTP. High amounts of dATP prevent inhibition by the closely related drug, 6-(p-hydroxyphenylazo)-isocytosine. A model is presented in which the inhibitors base-pair with the template while part of a ternary complex with the enzyme. These results imply that DNA polymerase III of B. subtilis is necessary for chromosomal replication.
The antimicrobial agent, 6 -(p-hydroxyphenylazo)-uracil (HPUra), specifically inhibits DNA synthesis in several Gram-positive bacteria (1) . In Bacillus subtilis, the inhibition is limited to replicative synthesis, while repair synthesis and DNA synthesis directed by several bacteriophages is unimpaired (2, 3) . Semiconservative DNA synthesis in toluenetreated B. subtilis cells is inhibited by HPUra in the presence of reducing agents (4) .
Recently, we described a mutant of B. subtilis lacking the DNA polymerase isolated by Okazaki and Kornberg (polymerase I) (5, 6) . In these polA -cells, the residual DNA-polymerizing activity has markedly different properties from polymerase I (5) . During the analysis of this residual activity we have isolated two additional DNA polymerases that we call polymerases II and III, in order of discovery. The three B. subtilis polymerases are similar to the correspondingly numbered Escherichia coli enzymes (7) (8) (9) (10) , but there are clear differences (11) . In this report, we show that HPUra specifically inhibits DNA polymerase III of B. subtili8 by an unexpected mechanism.
MATERIALS AND METHODS
Bacteria. Strain BC26 (phe-, argA-) was obtained from Dr. J. Copeland. The polA59 locus in HA101(59)F (5) was introduced into BC26 by transduction with bacteriophage PBS1 to form BC26(F). Among the phe+, argA+ transductants, the frequency of polA -bacteria is 95%.
Nucleotides and Nucleic Acids. Unlabeled nucleotides, poly(dA), poly(dT), and (dT)lo were purchased from P. L.
Biochemicals, poly[d(A-T)] from Miles Laboratories, and
salmon-testes DNA from Worthington Biochemical Corp. The deoxynucleotides were purified before use (5) . Labeled nucleotides were purchased from Schwarz BioResearch. Activation of salmon-testes DNA for use as a templateprimer for DNA polymerase used limited digestion by pancreatic DNase (4% acid-soluble A2w0) (11) . The concentration of nucleic acids is expressed as nucleotide equivalents.
Drugs. HPUra and 6-(p-hydroxyphenylazo)-2-amino-4-hydroxypyrimidine (HPIso) were generously provided by Dr. Bernard Langley of Imperial Chemical Industries, Ltd., Macclesfield, England. The removal of minor contaminants from HPUra by paper or column chromatography (1) did not alter the inhibitory activity of the drug. To convert the drug to an active inhibitor, 2.0 mM HPUra was treated with 25 mM dithiothreitol in 50 mM Tris* HCl (pH 7.5) at 370 for 21 min; longer incubation times result in a gradual loss of inhibitory activity. During the activation reaction the red color of the drug is lost at a rate that is directly proportional to the concentration of both HPUra and dithiothreitol; the second-order rate constants are 4.4 and 6.5 M-l min' at 300 and 370, respectively. Although the activated form (absorption maximum at 260-265 nm) can be readily purified from dithiothreitol and inactive drug by DEAE-cellulose chromatography, it rapidly reoxidizes in air to the colored form. Thus, for the experiments in this report, the activated drug was used without purification, and its concentration was assumed to be equal to the input inactive form.
Enzymes. Deoxyribonuclease I was purchased from Worthington Biochemical Corp. E. coli DNA polymerase I, Fraction 7 (12) , and T4 DNA polymerase, Fraction VII (13), were gifts of Dr. P. T. Englund. B. subtilia polymerase I was purified through the phosphocellulose chromatography step by the published method (6) . Purification and properties of polymerases II and III of B. subtilis are detailed elsewhere (11) . The specific activity of the polymerases II and III preparations used here were increased 2700-fold and 210-fold, respectively, over that of the crude extract of BC26(F) used in the purification. Fig. 1 . The degree of inhibition by the drug increases with time. Preincubation experiments with various components of the reaction mixture showed that the lag in inhibition is eliminated only when the preincubation mix contained HPUra and dithiothreitol. With preincubated drug, the onset of inhibition is immediate and the incorporation rate is linear with time (see Fig. 5 ), even when the drug is added after the polymerization reaction has begun. Therefore, dithiothreitol chemically converts the drug to an active form. The activa- Activation of HPUra at 300. The preincubation mixture contained 25 mM potassium phosphate (pH 7.4), 5 mM dithiothreitol, and 0.8 mM HPUra. At the times indicated aliquots were diluted 5-fold into an assay mixture with 0.025 unit of polymerase III and 40 uM triphosphates; the incorporation in a 5-min assay was monitored. The units of v are nucleotides incorporated, and vf is the velocity at maximal (83%) inhibition. The form of the plot is derived from the basic kinetic equations for inhibition and the definition of a first-order reaction (14) . tion is essential; no inhibition is obtained with unactivated drug even at 500-times the concentration, that gives 50% inhibition with the activated form. During activation the drug becomes colorless and a new absorption peak in the UV appears. The decoloration is a second-order reaction, but at the high dithiothreitol to HPUra ratios used in the activation reactions, pseudo first-order kinetics are observed. As shown in Fig. 2 , the conversion of HPUra to an active inhibitor is also a first-order reaction. Like the rate of color loss, the rate of formation of active inhibitor is augmented by an increase in the dithiothreitol concentration. For unknown reasons, the the calculated rate of activation is about twice that of color loss. Several other reducing agents such as reduced glutathione, cysteine, TPNH, and ascorbic acid both activate and reduce the drug, although all do so more slowly than dithiothreitol. Oxidized glutathione neither activates nor decolorizes HPUra. Fig. 3 shows a dose-response curve for inhibition by activated HPUra; the linear relationship between reciprocal velocity and HPUra concentration implies that the reaction of drug with the enzyme is uncomplicated (14) .
Enzyme Specificity of HPUra. With the activated drug in hand, we tested the effect of HPUra on four other DNA polymerases. An activated DNA template was used in all cases. Even at 100-to 1000-times the HPUra concentration that gives 50% inhibition of B. subtilis polymerase III, there was no inhibition of B. subtilis polymerase I, E. coli polymerase I, and T4 polymerase (the unactivated drug was also impotent). B. subtilis polymerase II was slightly inhibited; however, it was at least 500-fold less sensitive than B. subtilis polymerase III. Therefore, HPUra is a highly specific inhibitor of B. subtilis polymerase III. Site of Action of HPUra. Since HPUra does not inhibit several DNA polymerases, it is unlikely that it affects the template and not the enzyme, as some other DNA polymerase inhibitors (15) . Indeed, preincubation of the drug and template did not alter the degree of inhibition, nor did the addition of more template to an inhibited reaction. Increasing the template concentration from 0.3 mM, already a saturating level, to 1.0 mM also did not diminish inhibition. Therefore, it seems likely that HPUra interacts directly with DNA polymerase III. f-O, no HPUra; * -, 25 MM HPUra; * -, 100 AM HPUra. (B) To minimize dGTP depletion during the assay in the absence of HPUra, the reaction mixture was altered by increasing the total volume to 0.3 ml and decreasing the enzyme to 0.004 unit and the reaction time to 7 min.
Competitive Attenuation of Inhibition by dGTP. An unexpected finding of the study of toluene-treated cells was that HPUra inhibition is abolished by high amounts of dGTP (16) . The effect is the same on polymerase III. In Fig. 4 , double-reciprocal plots of reaction velocity as a function of dGTP concentration at two concentrations of activated HPUra are shown. HPUra inhibition is competitive with dGTP concentration since the maximum velocity is not altered by the presence of inhibitor. From these and other data the Km for dGTP is calculated to be 6 X 10-7 M and the Kj for HPUra to be 3 to 6 X 10-7 M. The following nucleotides at 0.2 mM did not alter the degree of inhibition by 20 AM HPUra: rGTP, dGDP, dGMP, dATP, dTTP, and dCTP; in the same experiment 0.2 mM dGTP abolished inhibition. The only nucleotide, other than dGTP, that we have found to attenuate inhibition is dITP, which, like dGTP, base-pairs with C residues. Maximal activity requires a higher concentration of dITP than dGTP, and thus a higher concentration of dITP is needed to diminish inhibition. With no dGTP in the assay mixture, the inhibition by 3 MM drug was 86, 63, 25, and 6% at 0, 4.0, 90, and 480MM dITP, respectively.
Inhibition by HPUra Is Reversible. Addition of dGTP or dilution of the reaction mix reduced the inhibition by activated HPUra to the level expected of a reversible inhibitor (Fig. 5) . Thus, polymerase III is not irreversibly inactivated by HPUra.
Inhibition by HPIso Is Reversed by dA TP. HPIso is an analogue of HPUra in which the pyrimidine 2-keto group in HPUra is replaced by an amino moiety. Like HPUra, HPIso must be reduced to be an inhibitor of B. subtilis polymerase III. Unlike HPUra, the inhibition is attenuated by dATP and not dGTP, as also found in toluene-treated B. subtitis cells (17) . Thus, an increase in the concentration of dATP from 5 MM to 200 MM in an assay reduced the inhibition by 20 MM HPIso from 87% to 17%, while addition of dAMP, dGTP, dTTP, or dCTP to 200MM was without effect. inhibitors of the reaction of dGTP and dATP, respectively, with B. subtilis polymerase III. Polymerase III catalyzes an extensive end-addition reaction in the absence of a-full triphosphate complement (11) . Under these conditions, it is clear that HPUra inhibits the incorporation of each of the four triphosphates. HPUra (100 MAM) inhibited the incorporation of 10 MAM dATP, dTTP, dCTP, and dGTP alone by 92, 96, 85, and 77%, respectively. A dose-response curve for the inhibition of synthesis with dGTP missing from the full triphosphate complement is plotted in Fig. 6 . The Ki is 6 X 10-7 M or about the same as that obtained in the presence of dGTP. Thus, HPUra prevents the incorporation of all four triphosphates while only dGTP attenuates inhibition.
A simple model consistent with the data postulates that HPUra binds to an enzyme-template replicative complex only when C is the base to be copied (T for HPIso); the HPUra hydrogen-bonds to the C residue. This ternary complex, enzyme-template-inhibitor, decreases the amount of enzyme available for polymerization. Since only dGTP is accepted by a polymerase copying a C residue, only dGTP competes with HPUra.
One test of the model is provided by the experiments reported in Table 1 . Synthetic polymers were used to limit the template residues to A alone for (dT)lo poly(dA) and to A Proc. Nat. Acad. Sci. USA 70 (1973) subtilis, E. coli, and T4-infected cells are resistant to the drug. Third, the template probably must contain a C residue for HPUra inhibition (a T residue for HPIso inhibition). Fourth, the dGTP to HPUra ratio must not be too high (dATP for HPIso inhibition).
The inhibition model postulates that HPUra and HPIso occupy the triphosphate binding site of polymerase III, hydrogen bonding to C and T on the template, respectively. These are, of course, not the expected base pairs, but if an enol tautomer of the drug is present, then these specific pairs can be drawn. The 4-hydroxy tautomer of HPIso can make three good hydrogen bonds to T but cannot readily form two hydrogen bonds to the other bases within wobble limits (19) . Since HPUra has two carbonyl groups, two monoenolic isomers are possible. With the 4-hydroxy form, two hydrogen bonds can be formed to C but two hydrogen bonds cannot be made readily to G or A within wobble limits; bonding to T brings the keto groups rather close together. It is interesting to note that another uracil analogue, 3-deazauridine, has an enolic 4-hydroxyl group (20) . The 2-hydroxy derivative of HPUra can make three hydrogen bonds to C and cannot pair effectively to T and G; base pairing with A may be excluded on geometric grounds since HPUra and HPIso apparently bond like purines. These postulated base pairs do not require any significant tilting of the pyrimidine ring of the drug from the position of this ring in the purines of the Watson-Crick base pairs.
Whatever the precise structure of the base pairs*, the evidence that the drugs hydrogen-bond to the template is quite good. The binding of each of the drugs (which differ only in the pyrimidine moiety) to the template-enzyme complex is strong, but reversible, and base-specific both in its formation and its competition by triphosphates. Hydrogen bond-mediated base pairing is the most reasonable explanation of these properties. It is striking, and somewhat surprising, that the apparent affinity of the enzyme for HPUra and dGTP is the same, while dGDP and rGTP do not compete effectively with dGTP for polymerase III.
The contrast of HPUra with ara-CTP is instructive. While the effect of both drugs is enzyme-specific and reversed by a specific triphosphate for both E. coli (21) and B. subtilis DNA polymerases (11), ara-CTP has no effect on synthesis in the absence of dCTP (11) . Ara-CTP acts as a simple competitive inhibitor of dCTP incorporation while HPUra prevents the incorporation of all four triphosphates.
Evidence was presented that HPUra does not alter the template nonspecifically; nor does it inhibit by binding to a triphosphate to form a toxic analogue, since raising the concentration of either dATP, dCTP, or dTTP does nor reverse inhibition, even though the incorporation of each of these triphosphates is prevented by the drug.
There are several persuasive arguments for the inhibition of polymerase III being the site of action of HPUra in vivo. First, the reaction of HPUra with B. =ubtilis polymerase III is highly selective. Second, the in vitro reaction, like the inhibition of toluene-treated cells, is rapid in onset, is reversible by dilution or by dGTP (dATP for HPIso), and requires a reduced drug at only very low concentrations (the Kj, in vitro, is less than 1 AM). Third, the pattern of inhibition in vivo in affecting only the host, replicative DNA synthesis is clearly compatible with an action on a specific DNA polymerase. Therefore, it seems likely that B. subtilis polymerase III, like the correspondingly numbered E. coli enzyme (22) , is necessary for DNA replication (see note added in proof).
NOTE ADDED IN PROOF
We have selected a spontaneous mutant of B. subtilis resistant to HPUra and HPIso. The polymerase III of this mutant is resistant to the drugs, thereby confirming polymerase III is necessary for replication. * Dr. R. Wells has suggested an alternative bonding scheme that does not postulate enolic tautomers but rather base-pairing through the N-1 hydrogen, a hydrogen from the proximal nitrogen of the presumed hydrazine link, and the 2-carbonyl of HPUra or the amino of HPIso (personal communication).
